Biomedtracker
Subscription-based online market-intelligence and research platform focused on biopharma. Publishes indication- and disease-specific analyst reports and market-spotlights, captures and distributes anonymized expert (KOL) interviews, provides dashboard trackers of clinical and regulatory catalysts, aggregates third-party industry news, and maintains documented research standards and sourcing policies. Content is primarily available to institutional subscribers with downloadable support material.
Industries
Nr. of Employees
small (1-50)
Biomedtracker
London, England, United Kingdom, Europe
Products
Indication-specific Market Spotlight reports
Short-form, indication-focused market-spotlight reports providing epidemiology, market context and analyst summaries.
Long-range launch outlook reports
Multi-asset outlooks summarizing late-stage drugs projected for future launches including approval likelihoods, catalyst lists and downloadable support material.
Class and innovation analysis reports
Deep-dive reports tracing development and commercial dynamics for therapeutic classes.
Gene, Cell, & RNA Therapy Landscape
A comprehensive quarterly report analyzing regulatory activity, approvals, clinical development trends, dealmaking, and financing within the gene, cell, and RNA therapy landscape for Q2 2026.
Gene, Cell, & RNA Therapy Landscape Q1 2026
A comprehensive industry report analyzing regulatory approvals, accelerated pathways, dealmaking, and capital raises across gene, cell, and RNA therapies for the first quarter of 2026.
Biomedtracker
A pharmaceutical intelligence platform providing tracking on drug development, clinical trials, catalysts, and potential drug launches.
Indication-specific Market Spotlight reports
Short-form, indication-focused market-spotlight reports providing epidemiology, market context and analyst summaries.
Long-range launch outlook reports
Multi-asset outlooks summarizing late-stage drugs projected for future launches including approval likelihoods, catalyst lists and downloadable support material.
Class and innovation analysis reports
Deep-dive reports tracing development and commercial dynamics for therapeutic classes.
Gene, Cell, & RNA Therapy Landscape
A comprehensive quarterly report analyzing regulatory activity, approvals, clinical development trends, dealmaking, and financing within the gene, cell, and RNA therapy landscape for Q2 2026.
Gene, Cell, & RNA Therapy Landscape Q1 2026
A comprehensive industry report analyzing regulatory approvals, accelerated pathways, dealmaking, and capital raises across gene, cell, and RNA therapies for the first quarter of 2026.
Biomedtracker
A pharmaceutical intelligence platform providing tracking on drug development, clinical trials, catalysts, and potential drug launches.
Services
Analyst-authored market-spotlight and strategy reports covering specific indications and disease groups.
Recorded, transcribed and anonymized interviews and short surveys of clinical experts published to subscribers with regional coverage.
Ongoing listings of upcoming catalysts (trial readouts, regulatory filings) and impact events with links to company and event details and downloadable catalyst spreadsheets.
Curated aggregation of industry articles from multiple third-party feeds delivered via an online feed.
Curated disease and indication reports across broad therapy areas with taxonomy mapping to external resources.
Documentation of research sourcing, conflict-of-interest policies, handling of material non-public information and distribution rules for subscribers.
Analyst-authored market-spotlight and strategy reports covering specific indications and disease groups.
Recorded, transcribed and anonymized interviews and short surveys of clinical experts published to subscribers with regional coverage.
Ongoing listings of upcoming catalysts (trial readouts, regulatory filings) and impact events with links to company and event details and downloadable catalyst spreadsheets.
Curated aggregation of industry articles from multiple third-party feeds delivered via an online feed.
Curated disease and indication reports across broad therapy areas with taxonomy mapping to external resources.
Documentation of research sourcing, conflict-of-interest policies, handling of material non-public information and distribution rules for subscribers.
Expertise Areas
- Market intelligence and therapeutic-area analysis
- Indication and disease taxonomy curation (including rare diseases)
- High-volume report publishing, indexing and retrieval
- KOL research, interview capture, transcription and anonymized dissemination
Key Technologies
- Web-based searchable report library
- Taxonomy-driven filtering and disease mapping
- News-feed aggregation and curation pipelines
- PDF and spreadsheet (Excel) export and distribution
News & Updates
Release of a market-spotlight report covering Waldenström macroglobulinemia (lymphoplasmacytic lymphoma); includes epidemiology and clinical context.
Release of a market-spotlight report on norovirus epidemiology and clinical burden.
Release of a market-spotlight report on cutaneous T-cell lymphoma providing disease and market context.
Published anonymized KOL interview providing clinical practice perspective on AATD and mid- to late-stage pipeline assets.
Published anonymized KOL interview with regional clinical insights on AATD and pipeline therapies.
Published anonymized KOL interview with regional clinical insights on AATD and pipeline therapies.
Release of a market-spotlight report covering Waldenström macroglobulinemia (lymphoplasmacytic lymphoma); includes epidemiology and clinical context.
Release of a market-spotlight report on norovirus epidemiology and clinical burden.
Release of a market-spotlight report on cutaneous T-cell lymphoma providing disease and market context.
Published anonymized KOL interview providing clinical practice perspective on AATD and mid- to late-stage pipeline assets.
Published anonymized KOL interview with regional clinical insights on AATD and pipeline therapies.
Published anonymized KOL interview with regional clinical insights on AATD and pipeline therapies.